Acadia Pharmaceuticals ACAD Other income, net (Note 6)
Other income, net (Note 6) at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Acadia Pharmaceuticals's other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Acadia Pharmaceuticals's other income, net (note 6)?
- Acadia Pharmaceuticals (ACAD) reported other income, net (note 6) of $542K in Q1 2026.
- How has Acadia Pharmaceuticals's other income, net (note 6) changed year-over-year?
- Acadia Pharmaceuticals's other income, net (note 6) decreased by 7.8% year-over-year, from $588K to $542K.
- What is the long-term trend for Acadia Pharmaceuticals's other income, net (note 6)?
- Over 4 years (2021 to 2025), Acadia Pharmaceuticals's other income, net (note 6) has grown at a 3.8% compound annual growth rate (CAGR), from $2.04M to $2.37M.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.